HRTX Q3 2023 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M+18.4% YoY

Gross Profit

$13M42.1% margin

Operating Income

-$25M-79.3% margin

Net Income

-$25M-79.6% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

-1.0%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$10M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$229M

Total Liabilities

$257M

Stockholders' Equity

-$28M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$27M	+18.4%
Gross Profit	$13M	$12M	+11.7%
Operating Income	-$25M	-$42M	+40.5%
Net Income	-$25M	-$42M	+40.3%